<DOC>
	<DOCNO>NCT02040090</DOCNO>
	<brief_summary>The purpose study : 1 . Evaluate safety tolerability KamRAB comparison HRIG comparator product . 2 . To assess whether KamRAB interfere development self active antibody give simultaneously active rabies vaccine , compare HRIG comparator product , also give conjunction active rabies vaccine .</brief_summary>
	<brief_title>Phase II/III Study Safety Effectiveness HRIG With Co-administration Active Rabies Vaccine Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Able willing sign inform consent . Healthy male female subject 18 75 year age inclusive previously immunize rabies . Ability comply completion home diary . No previous exposure Rabies epidemic , Rabies vaccine and/or Rabies Immune globulin . No significant abnormality serum hematology , serum chemistry serum immunogenic marker ( C3 , C4 C50 ) accord Principal Investigator 's judgment . No significant abnormality urinalysis accord Principal Investigator 's judgment . No significant abnormality ECG per investigator judgment . Nonpregnant , nonlactating female subject , whose screening pregnancy test negative use contraceptive method deem reliable investigator , 5 year postmenopausal surgically sterilize . Male subject must use least one effective contraceptive method study start throughout entire duration study . History laboratory evidence IgA deficiency . A history previous administration rabies vaccine HRIG . History live virus vaccine administration , e.g. , measles vaccine , within last 3 month . History anaphylactic anaphylactoid hypersensitivity reaction chicken egg ; history mild allergic reaction chicken egg , e.g. , skin rash , exclusion criterion History hypersensitivity reaction follow component active rabies vaccine ( USFDA approve ) e.g . : neomycin , bovine gelatin , trace amount chicken protein , chlortetracycline , amphotericin B accordance product insert vaccine . History hypersensitivity reaction component equivalent active Rabies vaccine . History allergy blood blood product . History bleed disorder . Fever time start infusion . ( Oral temperature &gt; 38ÂºC . ) Clinically significant intercurrent illness include : cardiac , hepatic , renal , endocrine , neurological , hematological , neoplastic , immunological , skeletal ) opinion investigator , could interfere safety , compliance aspect study . Evidence active systemic infection require treatment antibiotic within 2 week time drug administration . Evidence uncontrolled hypertension ( systolic blood pressure &gt; 150 mm Hg , and/or diastolic blood pressure &gt; 100 mm Hg ) . Heart rate &gt; 120/min . Weight &gt; 93.75 kg Pregnancy and/or lactation . Woman childbearing potential take adequate contraception deem reliable investigator . All type malignancy except basal squamous cell ( scaly platelike ) skin cancer situ cervical carcinoma must remission minimum 5 years. , For nonmelanoma skin cancer carcimona insitu cervix may enrol treat cured time screen . Previous organ transplant recipient . Evidence ongoing infection HAV , HCV , HBV , HIV 1/2 ) . Presence psychiatric disorder , mental disorder medical disorder might impair subject 's ability give inform consent comply requirement study protocol . Previous enrolment study . Participation another clinical trial within 30 day prior baseline visit . Evidence alcohol abuse history alcohol abuse illegal and/or legally prescribe drug past 10 year . History life threaten allergy , anaphylactic reaction , systemic response human plasma derive product . Known hypersensitivity ingredient excipients study drug . Any factor , opinion investigator , would prevent subject complying requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>